Literature DB >> 8334673

Scientific basis for cancer prevention. Intermediate cancer markers.

J L Mulshine1, M Jett, F Cuttitta, A M Treston, K Quinn, F Scott, N Iwai, I Avis, R I Linnoila, G L Shaw.   

Abstract

Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin-releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334673     DOI: 10.1002/1097-0142(19930801)72:3+<978::aid-cncr2820721305>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Enhancing quality of retrieval through concept edit history.

Authors:  Francis W Hartel; Gilberto Fragoso; Kim L Ong; Robert Dionne
Journal:  AMIA Annu Symp Proc       Date:  2003

Review 2.  Cancer risk assessment.

Authors:  B Walker
Journal:  J Natl Med Assoc       Date:  1997-01       Impact factor: 1.798

Review 3.  Cancer prevention in primary care. Current trends and some prospects for the future--II.

Authors:  J Austoker
Journal:  BMJ       Date:  1994 Aug 20-27

Review 4.  The Snark was a Boojum - reloaded.

Authors:  Simone Macrì; S Helene Richter
Journal:  Front Zool       Date:  2015-08-24       Impact factor: 3.172

5.  Translational Research in Oncology: Implications for Palliative Care.

Authors:  Arunangshu Ghoshal
Journal:  Indian J Palliat Care       Date:  2017 Oct-Dec

6.  Beyond bench and bedside: disentangling the concept of translational research.

Authors:  Anna Laura van der Laan; Marianne Boenink
Journal:  Health Care Anal       Date:  2015-03

7.  Major milestones in translational oncology.

Authors:  Tommaso A Dragani; Antoni Castells; Vathany Kulasingam; Eleftherios P Diamandis; Helena Earl; Wade T Iams; Christine M Lovly; J P Michiel Sedelaar; Jack A Schalken
Journal:  BMC Med       Date:  2016-07-28       Impact factor: 8.775

8.  Translational Research in Endocrinology.

Authors:  Vin Tangpricha
Journal:  J Clin Transl Endocrinol       Date:  2014-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.